Dallasco 2021 Novità Sul Ruolo Del T-Dxd

Dall’ASCO 2021 novità sul ruolo del T-DXd

EBCC14, temi e domande aperte: tra queste, T-DXd nei pazienti HER2-…

Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer

Dr Tarantino on Updated Survival Data With T-DXd in HER2+ Breast Cancer

Dr Tarantino on the Safety of T-DXd and T-DM1 in HER2+ Breast Cancer

DESTINY-Breast04: exploring T-DXd and IO combinations in HER2-low breast cancer

DESTINY-Breast12: T-DXd in patients with HER2+/HR- breast cancer with brain metastasis

Dr Lin on the Efficacy of T-DXd in HER2+ Advanced Breast Cancer With CNS Metastases

Trastuzumab deruxtecan in patients with breast cancer with brain metastases

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previo...

TUXEDO-1: T-DXd for patients with HER2-positive breast cancer and brain metastasis

Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer

DESTINY-Breast03, risultati importanti per trastuzumab deruxtecan

DESTINY-Breast04: T-DXd for patients with HER2-low mBC

Highlights on T-DXd in pretreated HER2-expressing solid tumours : The DESTINY-PanTumor02 study

European Society for Medical Oncology (ESMO)

HER2CLIMB-04: tucatinib plus T-DXd for HER2+ breast cancer

DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1

DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markers

Choosing between tucatinib and T-DXd in HER2+ breast cancer

Dr Curigliano on the Efficacy of T-DXd in HER2-Low and HER2-Ultralow Breast Cancer